SEARCH

SEARCH BY CITATION

References

  • Bangsberg, D., S. Perry, E. Charlebois, R. Clark, M. Roberston, A. Zolopa, A. Moss. 2001. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15(9): 11811183.
  • Behrens, D., J. Caulkins, G. Tragler, G. Feichtinger. 2000. Optimal control of drug epidemics: Prevent and treat—but not at the same time? Manage. Sci. 46(3): 333347.
  • Boyd, S., L. Vandenberghe. 2004. Convex Optimization. Cambridge University Press, New York.
  • Byakika-Tusiime, J., J. Crane, J. Oyugi, K. Ragland, A. Kawuma, P. Musoke, D. Bangsberg. 2009. Longitudinal antiretroviral adherence in HIV+ Ugandan parents and their children initiating HAART in the MTCT-Plus family treatment model: Role of depression in declining adherence over time. AIDS Behav. 13(S1): 8291.
  • Carr, C., J. Jallah. 2008. Improving spatial accessibility to antiretroviral treatments for HIV/AIDS. Unpublished Master's Thesis, MIT-Zaragoza Logistics Center, Cambridge, MA.
  • Castilla, J., J. del Romero, V. Hernando, B. Marincovich, S. García, C. Rodríguez. 2005. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J. Acquir. Immune Defic. Syndr. 40(1): 96101.
  • Central Statistical Office of Zambia. 2011. 2010 Census of population and housing: Preliminary report. Available at http://www.zamstats.gov.zm/ (accessed date March 17, 2011).
  • Cohen, M., Y. Chen, M. McCauley, T. Gamble, M. Hosseinipour, N. Kumarasamy, J. Hakim, J. Kumwenda, B. Grinsztejn, J. Pilotto, S. Godbole, S. Mehendale, S. Chariyalertsak, B. Santos, K. Mayer, I. Hoffman, S. Eshleman, E. Piwowar-Manning, L. Wang, J. Makhema, L. Mills, G. de Bruyn, I. Sanne, J. Eron, J. Gallant, D. Havlir, S. Swindells, H. Ribaudo, V. Elharrar, D. Burns, T. Taha, K. Nielsen-Saines, D. Celentano, M. Essex, T. Fleming, the HPTN 052 Study Team. 2011. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365(6): 493505.
  • de Olalla, P., H. Knobel, A. Carmona, A. Guelar, J. López-Colomés, J. Caylà. 2002. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 30(1): 105110.
  • Duintjer Tebbens, R., K. Thompson. 2009. Priority shifting and the dynamics of managing eradicable infectious diseases. Manage. Sci. 55(4): 650663.
  • Gold, M., J. Siegel, L. Russell, M. Weinstein. 1996. Cost-Effectiveness in Health and Medicine. Oxford University Press, New York.
  • Golin, C., H. Liu, R. Hays, L. Miller, C. Beck, J. Ickovics, A. Kaplan, N. Wenger. 2002. A prospective study of predictors of adherence to combination antiretroviral medication. J. Gen. Int. Med. 17(10): 756765.
  • Gray, R., M. Wawer, R. Brookmeyer, N. Sewankambo, D. Serwadda, F. Wabwire-Mangen, T. Lutalo, X. Li, T. vanCott, T. Quinn. 2001. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357(9263): 11491153.
  • Gupta, R., M. Jordan, B. Sultan, A. Hill, D. Davis, J. Gregson, A. Sawyer, R. Hamers, N. Ndembi, D. Pillay, S. Bertagnolio. 2012. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: A global collaborative study and meta-regression analysis. Lancet 380(9849): 12501258.
  • Hardon, A., S. Davey, T. Gerrits, C. Hodgkin, H. Irunde, J. Kgatlwane, J. Kinsman, A. Nakiyemba, R. Laing. 2006. From access to adherence: The challenges of antiretroviral treatment. Technical report. World Health Organization, Geneva, Switzerland.
  • Harries, A., D. Nyangulu, N. Hargreaves, O. Kaluwa, F. Salaniponi. 2001. Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 358(9279): 410414.
  • Hethcote, H. 2000. The mathematics of infectious diseases. SIAM Rev. 42(4): 599653.
  • HHS and CDC. 2005. Treatment of latent tuberculosis infection: Maximizing adherence. Available at http://www.cdc.gov/tb/publications/factsheets/treatment/LTBIadherence.pdf (accessed date December 8, 2009).
  • Holmes, J., F. Williams, L. Brown. 1972. Facility location under a maximum travel restriction: An example using day care facilities. Geographical Anal. 4(3): 258266.
  • Howe, J., P. Richards (eds). 1984. Rural Roads and Poverty Alleviation. Intermediate Technology Publications, London.
  • Jaiswal, A., V. Singh, J. Ogden, J. Porter, P. Sharma, R. Sarin, V. Arora, R. Jain. 2003. Adherence to tuberculosis treatment: Lessons from the urban setting of Delhi, India. Trop. Med. Int. Health 8(7): 625633.
  • Karlin, S., C. Carr. 1962. Prices and optimal inventory policy. K. Arrow, S. Karlin, H. Scarf, eds. Studies in Applied Probability and Management Science. Stanford University Press, Stanford, CA, 159172.
  • Keeling, M., P. Rohani. 2008. Modeling Infectious Diseases in Humans and Animals. Princeton University Press, Princeton, NJ.
  • Kraiselburd, S., P. Yadav. 2013. Supply chains and global health: An imperative for bringing operations management scholarship into action. Prod. Oper. Manag. 22(2): 377381.
  • Larson, R. 2007. Simple models of influenza progression within a heterogeneous population. Oper. Res. 55(3): 399412.
  • Lemaire, J. 1979. Managing sickle cell anemia in Zaire. Manage. Sci. 25(9): 922928.
  • Lima, V., R. Harrigan, D. Bangsberg, R. Hogg, R. Gross, B. Yip, J. Montaner 2009. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J. Acquir. Immune Defic. Syndr. 50(5): 529536.
  • Long, E., M. Brandeau, D. Owens. 2009. Potential population health outcomes and expenditures of HIV vaccination strategies in the United States. Vaccine 27(39): 54025410.
  • Long, E., N. Vaidya, M. Brandeau. 2008. Controlling co-epidemics: Analysis of HIV and tuberculosis infection dynamics. Oper. Res. 56(6): 13661381.
  • Mannheimer, S., G. Friedland, J. Matts, C. Child, M. Chesney. 2002. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin. Infect. Dis. 34(8): 11151121.
  • Mannheimer, S., J. Matts, E. Telzak, M. Chesney, C. Child, A. Wu, G. Friedland. 2005. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care 17(1): 1022.
  • McHutchison, J., M. Manns, K. Patel, T. Poynard, K. Lindsay, C. Trepo, J. Dienstag, W. Lee, C. Mak, J. Garaud, J. Albrecht. 2002. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123(4): 10611069.
  • Meredith, J. 1977. Managing the incidence of sickle cell anemia through genetic counseling. Manage. Sci. 23(12): 12611272.
  • Mills, E., J. Nachega, D. Bangsberg, S. Singh, B. Rachlis, P. Wu, K. Wilson, I. Buchan, C. Gill, C. Cooper. 2006. Adherence to HAART: A systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 3(11): 20392064.
  • Mishra, P., E. Hansen, S. Sabroe, K. Kafle. 2005. Socio-economic status and adherence to tuberculosis treatment: A case–control study in a district of Nepal. Int. J. Tuberculosis Lung Dis. 9(10): 11341139.
  • Munro, S., S. Lewin, H. Smith, M. Engel, A. Fretheim, J. Volmink. 2007. Patient adherence to tuberculosis treatment: A systematic review of qualitative research. PLoS Med. 4(7): 12301245.
  • Orrell, C., D. Bangsberg, M. Badri, R. Wood. 2003. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 17(9): 13691375.
  • Oyugi, J., J. Byakika-Tusiime, E. Charlebois, C. Kityo, R. Mugerwa, P. Mugyenyi, D. Bangsberg. 2004. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J. Acquir. Immune Defic. Syndr. 36(5): 11001102.
  • Oyugi, J., J. Byakika-Tusiime, K. Ragland, O. Laeyendecker, R. Mugerwa, C. Kityo, P. Mugyenyi, T. Quinn, D. Bangsberg. 2007. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 21(8): 965971.
  • Paterson, D., S. Swindells, J. Mohr, M. Brester, E. Vergis, C. Squier, M. Wagener, N. Singh. 2000. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Int. Med. 133(1): 2130.
  • Porter, G.. 2002. Living in a walking world: Rural mobility and social equity issues in sub-Saharan Africa. World Dev. 30(2): 285300.
  • Quinn, T., M. Wawer, N. Sewankambo, D. Serwadda, C. Li, F. Wabwire-Mangen, M. Meehan, T. Lutalo, R. Gray. 2000. Viral load and heterosexual transmission of Human Immunodeficiency Virus Type I. N. Engl. J. Med. 342(13): 921929.
  • Rahaman, M., K. Aziz, M. Munshi, Y. Patwari, M. Rahman. 1982. A diarrhea clinic in rural Bangladesh: Influence of distance, age, and sex on attendance and diarrheal mortality. Am. J. Public Health 72(10): 11241128.
  • Reilley, B., R. Abeyasinghe, M. Pakianathar. 2002. Barriers to prompt and effective treatment of malaria in northern Sri Lanka. Trop. Med. Int. Health 7(9): 744749.
  • ReVelle, C. 1986. The maximum capture or “sphere of influence” location problem: Hotelling revisited on a network. J. Reg. Sci. 26(2): 343358.
  • ReVelle, C., W. Lynn, F. Feldmann. 1969. An optimization model of tuberculosis epidemiology. Manage. Sci. 16(4): B190B211.
  • Sanders, G., A. Bayoumi, V. Sundaram, S. Bilir, C. Neukermans, C. Rydzak, L. Douglass, L. Lazzeroni, M. Holodniy, D. Owens. 2005. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N. Engl. J. Med. 352(6): 570585.
  • Schneider, H., D. Blaauw, L. Gilson, N. Chabikuli, J. Goudge. 2006. Health systems and access to antiretroviral drugs for HIV in southern Africa: Service delivery and human resources challenges. Reprod. Health Matters 14(27): 1223.
  • Shargie, E., B. Lindtjørn. 2007. Determinants of treatment adherence among smear-positive pulmonary tuberculosis patients in southern Ethiopia. PLoS Med. 4(2): 02800287.
  • Spiliotopoulou, E., M. Boni, P. Yadav. 2011. Impact of treatment heterogeneity on drug resistance and supply chain costs. Working paper, MIT-Zaragoza Logistics Center, Cambridge, MA.
  • Stock, R. 1983. Distance and the utilization of health facilities in rural Nigeria. Soc. Sci. Med. 17(9): 563570.
  • Taiwo, B., J. Idoko, L. Welty, I. Otoh, G. Job, P. Iyaji, O. Agbaji, P. Agaba, R. Murphy. 2010. Assessing the virologic and adherence benefits of patient-selected HIV treatment partners in a resource-limited setting. J. Acquir. Immune Defic. Syndr. 54(1): 8592.
  • Talluri, K., G. van Ryzin. 2005. The Theory and Practice of Revenue Management. Springer, New York.
  • Tuller, D., D. Bangsberg, J. Senkungu, N. Ware, N. Emenyonu, S. Weiser. 2009. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: A qualitative study. AIDS. Behav. 14(4): 778784.
  • UNAIDS. 2010. UNAIDS Report on the Global AIDS Epidemic. Available at http://www.unaids.org/documents/20101123_GlobalReport_em.pdf (accessed date June 10, 2011).
  • van der Werf, T., G. Dade, T. van der Mark. 1990. Patient compliance with tuberculosis treatment in Ghana: Factors influencing adherence to therapy in a rural service programme. Tubercle 71(4): 247252.
  • Ware, N., M. Wyatt, D. Bangsberg. 2006. Examining theoretic models of adherence for validity in resource-limited settings: A heuristic approach. J. Acquir. Immune Defic. Syndr. 43(S1): 1822.
  • Wawer, M., N. Sewankambo, D. Serwadda, T. Quinn, L. Paxton, N. Kiwanuka, F. Wabwire-Mangen, C. Li, T. Lutalo, F. Nalugoda, C. Gaydos, L. Moulton, M. Meehan, S. Ahmed, the Rakai Project Study Group, R. Gray. 1999. Control of sexually transmitted diseases for AIDS prevention in Uganda: A randomised community trial. Lancet 353(9152): 525535.
  • WHO. 2011a. Global Plan to Stop TB. Available at http://www.stoptb.org/global/plan/ (accessed date September 2, 2011).
  • WHO. 2011b. World Health Organization. Available at http://www.who.int/ (accessed date September 2, 2011).
  • Zaric, G., M. Brandeau. 2001. Optimal investment in a portfolio of HIV prevention programs. Med. Decis. Making 21(5): 391408.
  • Zaric, G., M. Brandeau, P. Barnett. 2000. Methadone maintenance and HIV prevention: A cost-effectiveness analysis. Manage. Sci. 46(8): 10151031.